...
首页> 外文期刊>Oncology letters >Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer
【24h】

Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer

机译:多种肿瘤相关抗原(TAA)的微型阵列在乳腺癌的免疫诊断中

获取原文
获取原文并翻译 | 示例

摘要

Sera from patients with cancer contain antibodies which react with a unique group of autologous cellular antigens called tumor-associated antigens (TAAs). This study aimed to determine whether a mini-array of multiple TAAs would enhance antibody detection and be a useful approach in breast cancer detection and diagnosis. The mini-array of multiple TAAs was composed of ten TAAs, including Imp1, p62, Koc, p53, c-myc, survivin, p16, cyclin B1, cyclin D1 and CDK2 full-length recombinant proteins. An enzyme-linked immunosorbent assay (ELISA) was used to detect antibodies against these ten TAAs in 41 sera from patients with breast cancer, as well as 82 sera from normal individuals. The antibody frequency of the individual TAAs in breast cancer was variable and ranged between 7.3 and 22.0%. With the successive addition of TAAs to a final total of ten antigens, there was a stepwise increase in positive antibody reactions, reaching a sensitivity of 61.0% and a specificity of 86.6% in breast cancer. The positive and negative likelihood ratios were 5.545 and 0.438, respectively, which showed that the clinical diagnostic value of a parallel assay of eight TAAs was high. The positive and negative predictive values were 73.5 and 82.0%, respectively, indicating that the parallel assay of eight TAAs raised the diagnostic precision significantly. The agreement rate and x-value were 79.7% and 0.52, respectively, while the Youden's Index (YI) was 0.5, indicating that the observed value of this assay had a middle range coincidence with the actual value. The data from the present study further support our previous hypothesis that the detection of autoantibodies for the diagnosis of certain types of cancer may be enhanced using a mini-array of several TAAs as target antigens. A customized antigen mini-array using a panel of appropriately selected TAAs is able to enhance autoantibody detection in the immunodiagnosis of breast cancer.
机译:患有癌症的患者的血清中含有的抗体会与一组独特的自体细胞抗原发生反应,这种抗原称为肿瘤相关抗原(TAA)。这项研究旨在确定多个TAA的微型阵列是否会增强抗体检测,并成为乳腺癌检测和诊断的有用方法。多个TAA的微阵列由十个TAA组成,包括Imp1,p62,Koc,p53,c-myc,survivin,p16,cyclin B1,cyclin D1和CDK2全长重组蛋白。酶联免疫吸附试验(ELISA)用于检测来自乳腺癌患者的41份血清以及来自正常个体的82份血清中针对这十种TAA的抗体。乳腺癌中单个TAA的抗体频率是可变的,介于7.3%和22.0%之间。通过将TAA连续添加到最终的十种抗原中,阳性抗体反应逐步增加,在乳腺癌中达到61.0%的敏感性和86.6%的特异性。阳性和阴性似然比分别为5.545和0.438,这表明八种TAA平行测定的临床诊断价值很高。阳性和阴性预测值分别为73.5%和82.0%,表明对8种TAA进行平行测定可显着提高诊断准确性。一致性率和x值分别为79.7%和0.52,而尤登指数(YI)为0.5,这表明该测定的观察值与实际值之间存在中等范围。来自本研究的数据进一步支持了我们先前的假设,即使用几种TAA的微型阵列作为靶抗原可以增强自身抗体的检测,以诊断某些类型的癌症。使用一组适当选择的TAA的定制抗原微型阵列能够增强乳腺癌免疫诊断中的自身抗体检测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号